Cover Image

Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach

Fabien Grimaud,1 Guillaume Penaranda,2 Chloé Stavris,3 Frédérique Retornaz,3 Véronique Brunel,4 Sylvie Cailleres,4 Hervé Pegliasco,5 Jacques Le Treut,5 Vincent Grisoni,6 Emilie Coquet,1 Laurent Chiche,3 Amélie Rognon1 1Department of Pharmacy, Hôpital Européen, Marseille, France; 2Department of Biost...

Full description

Saved in:

Bibliographic Details
Main Authors:	Grimaud F (Author), Penaranda G (Author), Stavris C (Author), Retornaz F (Author), Brunel V (Author), Cailleres S (Author), Pegliasco H (Author), Le Treut J (Author), Grisoni V (Author), Coquet E (Author), Chiche L (Author), Rognon A (Author)
Format:	Book
Published:	Dove Medical Press, 2021-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
by: Jiqiao Yang, et al.
Published: (2019)

PD-1/PD-L1 Inhibitors in Cervical Cancer
by: Yuncong Liu, et al.
Published: (2019)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
by: Peng-Fei Wang, et al.
Published: (2017)

IMMUNE RESISTANCE VIA A PD-1/PD-L1 MECHANISM IN GLIOBLASTOMA
by: V.S. KUSHNIROVA, et al.
Published: (2023)

PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study
by: Guili Huang, et al.
Published: (2022)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021)

Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis
by: Fabian Krutzek, et al.
Published: (2022)

PD-1 and PD-L1 expression in rare lung tumors
by: Marton Gyulai, et al.
Published: (2023)

The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface
by: Matyas Meggyes, et al.
Published: (2019)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
by: Ke Zhang, et al.
Published: (2022)

Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors
by: Jianing Chen, et al.
Published: (2022)

Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients
by: Takeru Kashiwada, et al.
Published: (2024)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
by: Maureen L. Drakes, et al.
Published: (2018)

Investigation of the PD-1/PD-L1 Expression in the Lesional Skins of Patients with Psoriasis
by: Selma Emre, et al.
Published: (2023)

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
by: Mengzhen Jiang, et al.
Published: (2023)

Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
by: Vishakha Singh, et al.
Published: (2021)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
by: Jian-ye Zhang, et al.
Published: (2020)

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
by: Ai L, et al.
Published: (2020)

PD-1/PD-L1 signaling in JIA synovial regulatory T cell function
by: van Wijk Femke, et al.
Published: (2011)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
by: Sara Zalba, et al.
Published: (2020)

Immunohistochemical Study of the PD-1/PD-L1 Pathway in Cutaneous Lupus Erythematosus
by: Zsófia Király, et al.
Published: (2022)

Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience
by: Fengze Sun, et al.
Published: (2022)

Percentages of PD-1+CD4+T cells and PD-L1+DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia
by: Yingying Wang, et al.
Published: (2018)

Biomarker recommendation for PD‐1/PD‐L1 immunotherapy development in pediatric cancer based on digital image analysis of PD‐L1 and immune cells
by: Manuel A Silva, et al.
Published: (2020)

Meningiomas and the tumor microenvironment: expression of PD-L1 and expression of PD-L1 and interferon-gamma in the prognosis
by: Gunter Gerson, et al.

A bibliometric analysis of research on PD-1/PD-L1 in urinary tract tumors
by: Yongming Chen, et al.
Published: (2024)

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
by: Chengliang Sun, et al.
Published: (2022)

Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment
by: Chen Chen, et al.
Published: (2021)

Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
by: Shun-Long Ou, et al.
Published: (2023)

The administration of PD-1 and PD-L1 inhibitors in pediatric hematology: a literature review
by: Aleksandra S. Paderina, et al.
Published: (2024)

A Comprehensive Computational Insight into the PD-L1 Binding to PD-1 and Small Molecules
by: Marialuigia Fantacuzzi, et al.
Published: (2024)

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
by: Pratibha Pandey, et al.
Published: (2022)

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
by: Laura Jimbu, et al.
Published: (2021)

Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test
by: Keyu Yuan, et al.
Published: (2022)

PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
by: Jiheun Han, et al.
Published: (2017)

Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
Published: (2020)

Relationship Between PD-L1, PD-1, CD8 and Clinicopathological Factors in Primary SCCs
by: Preslav Vasilev, et al.
Published: (2024)

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
by: Xiaoqiang Liu, et al.
Published: (2019)

Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer
by: Ryunosuke Hoshi, et al.
Published: (2024)